IRIS UniCatt

Rossetti, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.359
AS - Asia 1.598
EU - Europa 1.441
SA - Sud America 317
AF - Africa 90
Continente sconosciuto - Info sul continente non disponibili 78
OC - Oceania 5
Totale 5.888
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.241
SG - Singapore 705
CN - Cina 327
IT - Italia 266
BR - Brasile 246
FR - Francia 235
SE - Svezia 213
DE - Germania 161
VN - Vietnam 159
PL - Polonia 137
GB - Regno Unito 97
IN - India 93
IE - Irlanda 64
BD - Bangladesh 62
CA - Canada 61
ID - Indonesia 52
FI - Finlandia 48
JP - Giappone 44
ES - Italia 39
ZA - Sudafrica 35
MX - Messico 32
RU - Federazione Russa 32
UA - Ucraina 32
AR - Argentina 26
HK - Hong Kong 25
KR - Corea 20
IQ - Iraq 18
PT - Portogallo 18
AT - Austria 17
NL - Olanda 15
PH - Filippine 14
BE - Belgio 13
EC - Ecuador 13
TR - Turchia 13
LT - Lituania 12
CL - Cile 11
CO - Colombia 9
RO - Romania 9
CM - Camerun 8
IR - Iran 7
SA - Arabia Saudita 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
MA - Marocco 6
TW - Taiwan 6
VE - Venezuela 6
DZ - Algeria 5
GR - Grecia 5
UZ - Uzbekistan 5
AU - Australia 4
CI - Costa d'Avorio 4
EU - Europa 4
HR - Croazia 4
KE - Kenya 4
MY - Malesia 4
PK - Pakistan 4
AO - Angola 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
HN - Honduras 3
JM - Giamaica 3
JO - Giordania 3
LB - Libano 3
LV - Lettonia 3
NG - Nigeria 3
TH - Thailandia 3
UG - Uganda 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BS - Bahamas 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
CZ - Repubblica Ceca 2
EG - Egitto 2
GT - Guatemala 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LY - Libia 2
MD - Moldavia 2
ML - Mali 2
NI - Nicaragua 2
PA - Panama 2
PY - Paraguay 2
VI - Stati Uniti Isole Vergini 2
AL - Albania 1
AM - Armenia 1
BO - Bolivia 1
BW - Botswana 1
CG - Congo 1
GA - Gabon 1
GD - Grenada 1
GP - Guadalupe 1
GY - Guiana 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
Totale 5.802
Salva come PNG Salva come JPEG
Città #
Singapore 376
Chandler 320
San Jose 238
Ashburn 229
Kraków 108
New York 101
Beijing 76
Milan 73
Dublin 62
Ho Chi Minh City 59
Los Angeles 55
Lauterbourg 45
Tokyo 44
Jacksonville 43
Jakarta 42
Hanoi 37
Redmond 36
San Mateo 36
Boston 35
The Dalles 34
Rome 33
Frankfurt am Main 31
Hefei 30
St Louis 30
London 29
Paris 29
Wilmington 27
Orem 26
Houston 25
Princeton 24
Ann Arbor 23
Munich 23
Helsinki 22
Marseille 22
Cattolica 21
Warsaw 21
Johannesburg 20
Moscow 19
Nanjing 19
Atlanta 17
Dallas 17
Pune 17
Redwood City 17
Santa Clara 17
Chicago 16
Dearborn 16
Hong Kong 16
Montreal 16
Seattle 15
Catania 14
Madrid 13
São Paulo 13
Brussels 12
Nuremberg 12
Tukwila 12
Brooklyn 11
Phoenix 11
San Francisco 11
Seoul 11
Council Bluffs 10
Da Nang 10
Fairfield 10
Haiphong 10
Manchester 10
Nanchang 10
Stockholm 10
Toronto 10
Vienna 10
Buffalo 9
Kent 9
Norwalk 9
Ottawa 9
Poplar 9
Boardman 8
Charlotte 8
Dhaka 8
Düsseldorf 8
Lawrence 8
Miami 8
Woodbridge 8
Amsterdam 7
Brasília 7
Bremen 7
Changsha 7
Mumbai 7
Turku 7
Cusano Milanino 6
Davao City 6
Denver 6
Hebei 6
Lappeenranta 6
Mexico City 6
Porto 6
Queens 6
San Diego 6
Santiago 6
Turin 6
Washington 6
Bucharest 5
Guangzhou 5
Totale 3.122
Salva come PNG Salva come JPEG
Nome #
The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study 528
Whole-genome sequencing reveals host factors underlying critical COVID-19 266
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 194
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 184
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 168
An explainable model of host genetic interactions linked to COVID-19 severity 166
Cognitive reserve and neuropsychological functioning in older HIV-infected people 166
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 151
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 151
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 145
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 145
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 143
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 139
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 137
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 134
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 133
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 132
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 131
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 127
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 126
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 126
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 124
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 124
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 121
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 119
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 118
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 118
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 116
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 115
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 111
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 109
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 106
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 104
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 104
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 102
Treatment of HCV infection with the novel NS3/4A protease inhibitors 100
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 99
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 96
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 87
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 83
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 80
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 76
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 72
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 12
Totale 5.888
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.957
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.957
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022254 0 0 4 19 7 12 13 53 10 27 34 75
2022/2023887 96 105 53 116 61 100 32 77 101 70 58 18
2023/2024567 27 108 28 40 36 126 31 25 24 24 39 59
2024/2025923 30 40 91 52 106 43 52 50 99 71 155 134
2025/20262.329 331 51 122 315 464 100 367 95 115 207 81 81
2026/2027164 70 83 11 0 0 0 0 0 0 0 0 0
Totale 5.888